AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies, including superior quality human tissue samples and functional assays focused, as well as human primary cells through its subsidiary Cell Systems.


BiomimX develops the next generation of beating organs-on-chips. uBeat® Platforms and connected hardware provide 3D miniaturized constructs with a tunable mechanical stimulation to model human organs’ function and diseases. uBeat® products and customized drug screening services are available.

Newcells Biotech

Newcells Biotech uses 3D in vitro modelling expertise to develop nephrotoxicity and renal transporter assays that most accurately predict in vivo outcomes, as well as producing fully developed hiPSC-derived Retinal Organoids.


AlveoliX is a Swiss-based organ-on-chip company. Our product is comprised of different hardware components and the easy-to-handle organ-on-chip consumable AX12. On the AX12 healthy and diseased biomodels can be created to study drug safety and efficacy and to answer fundamental research questions.

Lena Biosciences

Lena Biosciences offers Perfused Organ Panel MPS with a Blood Substitute hemoglobin analog that yields a log-fold increase in CYP450 activity in primary human hepatocytes to identify mitotoxic metabolites and DILI. Services focus on efficacy and toxicity in liver, brain, tumor, and blood models.

Hesperos Inc.

Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.

CN Bio

CN Bio is a leading bioengineering company specializing in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of tomorrow’s medicines.

Altis Biosystems

Altis Biosystems has developed a stem cell platform that recreates the human intestinal epithelium, using proliferative stem cells and terminally differentiated cells. These cells are sourced from transplant-grade intestine. It is a high-throughput format, ideal for drug screening.


Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.